Stage of disease, resectability of the primary tumor, and BRAF-mutation status (in the unresectable or metastatic setting) are key parameters that influence the treatment paradigm of malignant melanoma. Combination regimens including Bristol-Myers Squibb’s Opdivo plus Yervoy, Novartis’s Tafinlar plus Mekinist, and Roche’s Zelboraf plus Cotellic are an integral part of the treatment algorithm for unresectable or metastatic disease. This content explores surveyed medical oncologists’ current treatment practices and the key factors that shape their prescribing choices.

Questions Answered

  • What is the uptake of immune checkpoint inhibitors and BRAF/MEK inhibitors for treatment of BRAF-mutation-positive patients, according to surveyed medical oncologists?
  • How do treatment practices for BRAF wild-type unresectable or metastatic malignant melanoma vary across the five European markets covered?
  • What are the drivers and constraints that influence treatment decisions in the unresectable or metastatic setting for select targeted therapies?
  • How do drug-treatment rates vary across key malignant melanoma patient populations, according to stage of disease and line of therapy?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

Markets covered: France, Germany, Italy, Spain, United Kingdom.

Primary research: Survey of approximately 50 medical oncologists in each EU5 country fielded in May 2018.

Key drugs covered:  Yervoy, Opdivo, Keytruda, Zelboraf, Tafinlar, Mekinist, Cotellic, Imlygic.

Table of contents

  • Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (EU5)
    • Current Treatment: Physician Insights Malignant Melanoma (EU5)

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, M.Pharm., Ph.D., is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her Ph.D. research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at G.J. University of Science & Technology, Hisar, India.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details